ReviewEuropean journal of nuclear medicine and molecular imaging2022
Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond.
Review in European journal of nuclear medicine and molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 67 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 1 synthesis or guideline pooled it, 117 citations in OpenAlex.
- Fibroblast Activation Protein Inhibitor (FAPI)-Based Theranostics-Where We Are at and Where We Are Heading: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Predictive value of [European journal of nuclear medicine and molecular imaging · 2025Trial
- Diagnostic efficacy of [European journal of nuclear medicine and molecular imaging · 2024Trial
- The role of [European journal of nuclear medicine and molecular imaging · 2023Trial
- Preclinical evaluation of homodimeric FAPI target modules for UniCAR-mediated targeting of FAP-expressing tumor and stromal cells.Oncoimmunology · 2026Article
- [⁶⁸Ga]Ga-CTR-FAPI versus [⁶⁸Ga]Ga-FAPI-04 PET/CT for patient evaluation in radioiodine-refractory differentiated thyroid cancer: A prospective comparative study.European journal of nuclear medicine and molecular imaging · 2026Article
- Intra-patient comparison of tracer uptake and biodistribution of [Annals of nuclear medicine · 2026Article
- Integrating RNA-seq and Single-Cell RNA-seq to Uncover Transcriptional Signature of Fibroblasts in Oral Squamous Cell Carcinoma.Biochemical genetics · 2026Article
- Molecular imaging-guided discovery of a potent natural FAPα inhibitor for liver fibrosis therapy.Nature communications · 2026Article
- FAPI: a solution to all, what about NENs?EJNMMI reports · 2026Review
- Gastrointestinal cancer with indeterminateOncology letters · 2026Article
- Development of LRRC15-binding disulfide-constrained peptides for PET imaging of cancer-associated fibroblasts.Nature communications · 2026Article
- Preclinical evaluation of novelAnnals of nuclear medicine · 2026Article
- Rational design of FAP-targeted sEVs delivered by microneedles for precision treatment of hypertrophic scars via ferroptosis in hypertrophic scar fibroblasts.Materials today. Bio · 2026Article
- Comparative evaluation of [European journal of nuclear medicine and molecular imaging · 2026Article
- Article
- The superiority of [European journal of nuclear medicine and molecular imaging · 2026Article
- Fibroblast Activation Protein-Targeted Radioligand Therapy (FAP RLT) in Gastroenteropancreatic Malignancies: Biological Rationale, Clinical Evidence, and Future Directions.World journal of nuclear medicine · 2026Review
- Tumour Microenvironment-Informed Radiotheranostics: Why and How Nuclear Medicine Could Advance Precision Oncology in the Decade Ahead.Pharmaceuticals (Basel, Switzerland) · 2026Review
- "FAPI-PET: a new chapter in oncologic molecular imaging".Annals of medicine and surgery (2012) · 2026Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Fibroblast activation protein (FAP) is a type II membrane-bound glycoprotein which is overexpressed in cancer-associated fibroblasts and activated fibroblasts at wound healing/inflammatory sites. Since the first clinical application of quinoline-based FAP ligands in 2018, FAP inhibitor (FAPI)-based PET imaging and radiotherapy have been investigated for a wide variety of diseases, both cancerous and non-cancerous. As a consequence, promising strides have been made in particular to improve the understanding of FAPI-based PET imaging and the potential value of FAPI-based tumor radiotherapy. Herein, we present a comprehensive review of radiolabeled FAPI, including their clinical translation, in order to clarify the current and potential future role of this class of molecules in nuclear medicine. In particular, this review underlines the value of FAPI radiopharmaceuticals in the diagnosis or therapy of tumors or benign conditions. However, limitations in present studies have hampered a precise evaluation of FAPI radiopharmaceuticals. Despite this, it will likely be worthwhile to further explore the clinical value of FAPI in diagnosis and therapy through better-designed and larger-population clinical trials in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.